NCT04273555
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients eligible for a new therapeutic regimen that includes HER2-targeted treatment and who are also naïve to that regimen
Exclusions: 
https://ClinicalTrials.gov/show/NCT04273555